SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders.  The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.

PRNewsWire • Feb 17, 2026

IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus

Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances multiple studies with key data ahead.

Zacks Investment Research • Feb 9, 2026

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

Seeking Alpha • Feb 6, 2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended December 31, 2025.

GlobeNewsWire • Feb 6, 2026

Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 55% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Feb 2, 2026

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026.

GlobeNewsWire • Jan 23, 2026

How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39%

The mean of analysts' price targets for Immunovant (IMVT) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Jan 15, 2026

Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?

Roivant Sciences Ltd. acquired 16,666,666 shares in a single open-market purchase on Dec. 12, 2025, for a transaction value of ~$350.0 million at $21.00 per share.

The Motley Fool • Dec 18, 2025

Share Offerings Prompt Huge Insider Buying in These 3 Biotechs

In the past week or so, secondary offerings from biotechs Immunovant Inc. (NASDAQ: IMVT), Kymera Therapeutics Inc.

24/7 Wall Street • Dec 17, 2025

Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement

Immunovant (IMVT) shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential best-in-class IgG reductions. I downgrade IMVT from "Strong Buy" to "Buy" due to competitive TED landscape and de-emphasis on batoclimab, despite robust upcoming catalysts. IMVT-1402 aims to address unmet needs in relapsed or uncontrolled GD patients, with pivotal data readouts expected in 2027 for additional indications like Myasthenia Gravis and difficult-to-treat rheumatoid arthritis.

Seeking Alpha • Dec 12, 2025